Antibiotic inhibiting ternary complex formation in ribosomal translation in Gram positive bacteria

We have identified an antibiotic drug lead, named MGC-10, which kills Gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), with a MIC (minimum inhibitory concentration) of 6 μM, while being harmless to mammalian cells in vitro in that concentration range. The antibacterial activity of MGC-10 was broad against over 50 strains of antibiotic-resistant samples obtained from hospital infections, where MGC-10 inhibited all tested strains of MRSA . The target for the MGC-10 activity is the ternary complex comprised of elongation factor Tu (EF-Tu), an aminoacylated tRNA (aa-tRNA), and guanosine triphosphate (GTP). Ternary complex delivers amino acids to the growing protein chain, bringing aa-tRNA into the codon-programmed A-site of the ribosome. MGC-10 appears to have potential as a topical treatment for difficult-to-treat wounds or skin infections by gram-positive pathogens such as MRSA. In a mouse skin-infection model with MRSA, MGC-10 performed as well or better than the present topical drug of choice, mupirocin. The drug showed little if any accumulation in the livers of topically treated mice.

Authors

Institutions

Publication Details

Journal
Invention Disclosure
Published
2026-02-14
DOI
https://doi.org/10.1016/j.inv.2026.100048
Primary Topic
RNA and protein synthesis mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antibiotic inhibiting ternary complex formation in ribosomal translation in Gram positive bacteria

Emanuel Goldman, Wlodek Mandecki
Invention Disclosure
RNA and protein synthesis mechanisms
article

Antibiotic inhibiting ternary complex formation in ribosomal translation in Gram positive bacteria

Emanuel Goldman, Wlodek Mandecki
article en

Abstract

We have identified an antibiotic drug lead, named MGC-10, which kills Gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), with a MIC (minimum inhibitory concentration) of 6 μM, while being harmless to mammalian cells in vitro in that concentration range. The antibacterial activity of MGC-10 was broad against over 50 strains of antibiotic-resistant samples obtained from hospital infections, where MGC-10 inhibited all tested strains of MRSA . The target for the MGC-10 activity is the ternary complex comprised of elongation factor Tu (EF-Tu), an aminoacylated tRNA (aa-tRNA), and guanosine triphosphate (GTP). Ternary complex delivers amino acids to the growing protein chain, bringing aa-tRNA into the codon-programmed A-site of the ribosome. MGC-10 appears to have potential as a topical treatment for difficult-to-treat wounds or skin infections by gram-positive pathogens such as MRSA. In a mouse skin-infection model with MRSA, MGC-10 performed as well or better than the present topical drug of choice, mupirocin. The drug showed little if any accumulation in the livers of topically treated mice.

Invention DisclosureVol. 6
Rutgers, The State University of New Jersey (US)
Good health and well-being
Openalex Percentile: Top 56%
RNA and protein synthesis mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.